Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
---|
10/31/2002 | WO2002085366A1 Aripiprazole oral solution |
10/31/2002 | WO2002085344A1 Noninvasive methods for treating hemangiomas |
10/31/2002 | WO2002085337A1 Micellar drug delivery systems for hydrophobic drugs |
10/31/2002 | WO2002085335A1 A novel coating for a sustained release pharmaceutical composition |
10/31/2002 | WO2002085333A1 Gastric juice-resistant device for releasing mucoadhesive active substance excipients and method for producing this gastric juice-resistant device |
10/31/2002 | WO2002085330A1 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
10/31/2002 | WO2002085328A2 Method for producing an active ingredient concentrate, and an active ingredient concentrate |
10/31/2002 | WO2002085326A2 Large, porous particles produced controlling humidity during a spray drying process |
10/31/2002 | WO2002085311A2 Hcg formulation |
10/31/2002 | WO2002085309A2 Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent |
10/31/2002 | WO2002085304A2 Proliposomal drug delivery system |
10/31/2002 | WO2002085300A2 Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts |
10/31/2002 | WO2002085299A2 Therapeutic treatments using the direct application of antimicrobial metal compositions |
10/31/2002 | WO2002085292A2 Improved method for treating aberrant fibrotic tisue manifestations with topical calcium channel blocker preparations and improved composition for such treatment and improved method for the manufacture thereof |
10/31/2002 | WO2002085283A2 Vaccine against tuberculosis |
10/31/2002 | WO2002085255A1 Improved surgical stent and method for preventing occlusion of stented vessels and conduits after implantation of stents |
10/31/2002 | WO2002085248A2 Prostanoids augment ocular drug penetration |
10/31/2002 | WO2002085113A1 Controlled release particles |
10/31/2002 | WO2002085112A1 A release pharmaceutical construct for gastric retention |
10/31/2002 | WO2002061105A9 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc) |
10/31/2002 | WO2002058750A3 A suspension comprising fibrinogen, thrombin and alcohol and a method of coating a carrier with the same |
10/31/2002 | WO2002053185A3 Anti-inflammatory use of polycationic compounds |
10/31/2002 | WO2002051535A3 Preparation of microparticles having improved flowability |
10/31/2002 | WO2002051385A8 Solid dispersions of nitrate active principles |
10/31/2002 | WO2002051356A3 Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections |
10/31/2002 | WO2002044230A3 Compositions containing copolymers based on acryloyldimethyl aminoethylsulfonic acid and synergistic additives |
10/31/2002 | WO2002043750A3 Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations |
10/31/2002 | WO2002040045A3 Microspheres of pancreatic enzymes with high stability |
10/31/2002 | WO2002040029A3 Corticosteroids adducts with natural polysaccharide polymers |
10/31/2002 | WO2002039977A3 A method for restoring a foot fat-pad |
10/31/2002 | WO2002026217A3 Composition for the transdermal delivery of fentanyl |
10/31/2002 | WO2002005800A3 Compositions for sustained release of analgesic agents, and methods of making and using the same |
10/31/2002 | WO2001087348A3 Multifunctional nanodevice platform |
10/31/2002 | WO2001067896A3 Method of producing oily suspensions of water-soluble vitamins |
10/31/2002 | WO2001054663A9 Surfactant free topical compositions and method for rapid preparation thereof |
10/31/2002 | WO2001053342A9 Chimeric prostate-homing peptides with pro-apoptotic activity |
10/31/2002 | WO2001052898A9 Methods for incorporating metal chelators at carboxyl-terminal site of peptides |
10/31/2002 | WO2001000198A3 Compositions and methods of treating cancer using compositions comprising an inhibitor of endothelin receptor activity |
10/31/2002 | US20020161201 For use in cancer diagnosis and therapy |
10/31/2002 | US20020161169 Hydrogel-forming system with hydrophobic and hydrophilic components |
10/31/2002 | US20020161134 Biodegradable triblock copolymers and process for their preparation |
10/31/2002 | US20020161052 Prodrug platforms capable of high degrees of loading |
10/31/2002 | US20020161035 Medicaments for chemotherapeutic treatment of disease |
10/31/2002 | US20020161032 Dosage form of a statin and microparticles of fenofibrate stabilized by a phospholipid surface active substrance; bioavailability unaffected by food intake |
10/31/2002 | US20020161020 Stablization of quinapril using magnesium oxide |
10/31/2002 | US20020161017 For amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to mammal |
10/31/2002 | US20020161016 As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation |
10/31/2002 | US20020160995 Suspended in a carrier host agent |
10/31/2002 | US20020160991 Orally-bioavailable formulations of fentanyl and congeners thereof |
10/31/2002 | US20020160982 Modafinil compound and cyclodextrin mixtures |
10/31/2002 | US20020160967 Sesame oil, medium-chain triglycerides, glycol esters or fatty acid esters and a cosolvent selected from polyhydric alcohols, cyclic carbonates, acetates, acetals, ketals, or castor oil |
10/31/2002 | US20020160964 Conjugates comprising galactose alpha 1,3 galactosyl epitopes and methods of using same |
10/31/2002 | US20020160943 Tumor-activated prodrug compounds and treatment |
10/31/2002 | US20020160942 Echinocandin/carbohydrate complexes |
10/31/2002 | US20020160938 At least one is a human or animal insulin analogue; coupled together with a diacid such as by reacting with suberic acid, bis(N-hydroxysuccinimidyl) ester |
10/31/2002 | US20020160515 Formation of polyampholytes in the presence of a polyion |
10/31/2002 | US20020160415 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for the prevention of cancer in at- risk subjects |
10/31/2002 | US20020160359 Stabilizing diluent for polypeptides and antigens |
10/31/2002 | US20020160109 Microencapsulation of drugs by solvent exchange |
10/31/2002 | US20020160050 Comprising one or more hydrophilic cellulose ether polymers, a hydrophilic melt binder, and a therapeutically active ingredient |
10/31/2002 | US20020160049 Emulsions as solid dosage forms for oral administration |
10/31/2002 | US20020160043 Dissolvable drug-containing dosage form for use in transmucosal delivery of drug to patient, comprising binding agent formed into solid matrix dissolvable in mouth, pharmacologically effective dosage of drug, buffer |
10/31/2002 | US20020160042 Injection molding method for neutral and acidic-group containing (meth)acrylate copolymers |
10/31/2002 | US20020160040 Cubic liquid crystalline compositions and methods for their preparation |
10/31/2002 | US20020160039 Infusing lipid/alcohol solution directly into aqueous polymer solution; resulting liposome which may be incorporated with a pharmaceutical substance consists of multilamellar vesicles of average size of 1-8 microns |
10/31/2002 | US20020160029 Stable hydroalcoholic compositions |
10/31/2002 | US20020159994 Toxin binding group is biotin or derivatives, spacers are 4,7,10-trioxa-1,13-tridecanediamine and trifunctional crosslinker is 5-amino-1,3-dicarboxylic acid or 3,5-diaminobenzoic acid |
10/31/2002 | US20020159956 Providing a chewing gum, includes a gum center and a coating coverings, coating includes a drug designed to be delivered into systemic system of indivisual |
10/31/2002 | US20020159952 Novel acoustically active drug delivery systems |
10/31/2002 | US20020159951 Administering to the patient a contrast agent comprising, in an aqueous carrier, targeted vesicles formulated from a lipid or polymer, a prfluorocarbon gas, a targeting ligand, scanning the patient using ultrasound to obtain an image |
10/31/2002 | US20020158226 Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
10/31/2002 | US20020157994 Production of pyrogen controlled water |
10/31/2002 | US20020157675 Compositions and medical procedure to treat snoring |
10/31/2002 | CA2791888A1 Proliposomal drug delivery system |
10/31/2002 | CA2681952A1 Drug delivery matrices to enhance wound healing |
10/31/2002 | CA2445740A1 Use of metals to treat inflammatory skin conditions |
10/31/2002 | CA2445734A1 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
10/31/2002 | CA2445729A1 Use of metals to treat mucosal membranes |
10/31/2002 | CA2444883A1 Microprojection array having a beneficial agent containing coating |
10/31/2002 | CA2444601A1 A release pharmaceutical construct for gastric retention |
10/31/2002 | CA2443937A1 Prostanoids augment ocular drug penetration |
10/31/2002 | CA2443587A1 Therapeutic treatments using the direct application of antimicrobial metal compositions |
10/31/2002 | CA2443518A1 Controlled release particles |
10/31/2002 | CA2436273A1 Method for producing an active ingredient concentrate, and an active ingredient concentrate |
10/30/2002 | EP1253150A1 Polymeric micellar structure |
10/30/2002 | EP1252897A1 Drugs for gene therapy |
10/30/2002 | EP1252896A2 Colon-specific drug release system |
10/30/2002 | EP1252887A1 Sustained-release preparation and process for producing the same |
10/30/2002 | EP1252885A2 Methods of preparing gas and gaseous precursor-filled microspheres |
10/30/2002 | EP1252883A1 Process for reducing partially or completely the symptoms associated with the histamin release within the human body |
10/30/2002 | EP1252882A1 Process to increase the threshold tolerance of the sensitive skin |
10/30/2002 | EP1252294A2 Compounds and methods for prevention and treatment of her-2/neu associated malignancies |
10/30/2002 | EP1252193A1 Water insoluble derivatives of polyanionic polysaccharides |
10/30/2002 | EP1252192A2 Enhancing the circulating half-life of antibody-based fusion proteins |
10/30/2002 | EP1252137A1 Palatable arginine compounds and uses thereof for cardiovascular health |
10/30/2002 | EP1251874A1 Stabilised pharmaceutical compositions and process for their preparation comprising an antibiotic and an expectorant |
10/30/2002 | EP1251871A1 Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants |
10/30/2002 | EP1251870A2 Novel use |
10/30/2002 | EP1251864A1 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release |
10/30/2002 | EP1251862A1 Ophthalmic compositions for treating ocular hypertension |